Treatment of NOD mice with a selective inverse agonist of RORα/γ, the main transcription factor involved in Th17 differentiation, significantly reduced diabetes incidence, insulitis, and proinflammatory cytokine expression [53], showing that Th17 differentiation blockade improves experimental diabetes. The gene discussed is RORA; the disease is diabetes mellitus.